Phase II trial of MVE-II in metastatic malignant melanoma.
作者信息
Rinehart J, LaForge J, Gochnour D, Neidhart J
出版信息
Cancer Immunol Immunother. 1987;24(3):244-6. doi: 10.1007/BF00205637.
Abstract
MVE-II, a low molecular weight fraction of pyran copolymer was utilized in a Phase II trial in patients with metastatic malignant melanoma. A total of 15 patients were investigated and no clinical responses or immunologic responses were observed. We concluded that MVE-II is not an active agent in malignant melanoma.
摘要
相似文献
1
Phase II trial of MVE-II in metastatic malignant melanoma.
Cancer Immunol Immunother. 1987;24(3):244-6. doi: 10.1007/BF00205637.
2
Evaluation of the immunological and toxicological properties of MVE-2 in phase I trials.
Cancer Res. 1983 May;43(5):2358-62.
3
Phase I study of MVE-2 evaluating toxicity and biologic response modification capability.
Cancer Immunol Immunother. 1986;22(1):68-71. doi: 10.1007/BF00205719.
4
Pyran (MVE-5) reverses the inhibition of macrophage receptors for cytophilic antibody induced by soluble immune complexes.
J Biol Response Mod. 1983;2(1):67-80.
5
Responsiveness of the Madison 109 lung carcinoma to maleic vinyl ether copolymer.
J Immunopharmacol. 1983;5(1-2):31-47. doi: 10.3109/08923978309026441.
6
Therapy of artificial and spontaneous metastases of murine tumors with maleic anhydride-divinyl ether-2.
Cancer Res. 1981 Jun;41(6):2378-85.
7
Immunomodulation and antitumor effects of MVE-2 in mice.
J Biol Response Mod. 1984 Dec;3(6):634-52.
8
Antimetastatic effects of maleic anhydride-divinyl ether in rats with mammary adenocarcinoma.
J Immunopharmacol. 1983;5(1-2):65-75. doi: 10.3109/08923978309026443.
9
Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2).
Cancer Chemother Pharmacol. 1986;18(3):243-6. doi: 10.1007/BF00273395.
10
Reduced incidence of rat colon cancer metastases by perioperative immunostimulation with maleic anhydride-divinyl ether-2 (MVE-2).
Dis Colon Rectum. 1985 Apr;28(4):217-21. doi: 10.1007/BF02554033.
本文引用的文献
1
The biological activity of the synthetic polyanion, pyran copolymer (diveema, MVE, 46015) and the heterocyclic bis DEAE fluorenone derivative, tilorone and congeners: clinical and laboratory effects of these agents as modulators of host resistance.
Pharmacol Ther. 1981;15(1):1-44. doi: 10.1016/0163-7258(81)90014-0.
2
Evaluation of the immunological and toxicological properties of MVE-2 in phase I trials.
Cancer Res. 1983 May;43(5):2358-62.
3
Effect of interferon inducers and interferon on bacterial infections.
Antimicrob Agents Chemother. 1972 Jan;1(1):80-1. doi: 10.1128/AAC.1.1.80.
4
Combined drug and immunostimulation therapy against a syngeneic murine leukemia.
J Natl Cancer Inst. 1974 Feb;52(2):463-8. doi: 10.1093/jnci/52.2.463.
5
Divinyl ether-maleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity.
Nature. 1973 Nov 16;246(5429):160-2. doi: 10.1038/246160a0.
6
The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy.
Cancer Invest. 1986;4(1):29-42. doi: 10.3109/07357908609039825.
7
Effect of maleic anhydride-divinyl ether copolymers on experimental M109 metastases and macrophage tumoricidal function.
Cancer Treat Rep. 1978 Nov;62(11):1817-22.
8
9
Relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinyl ether (MVE) polyanions.
Cancer Treat Rep. 1978 Nov;62(11):1797-803.
Zotero 插件